Run on the highly portable LumiraDx Platform, the LumiraDx NT-proBNP test is a quantitative, fingerstick blood assay designed for near-patient testing with lab-comparable results in 12 minutes. It is ...

Dallas, TX - The addition of natriuretic peptide testing to the traditional clinical evaluation of patients with dyspnea of suspected cardiac origin cut the duration of emergency-department visits by ...

Scientists develop new blood test to identify individuals at high risk of developing hypertrophic cardiomyopathy, most common ...

"HF algorithms are starting to recognize and include NT-proBNP in identifying stage B HF…Studies such as ours could provide insight and guidance as to when repeat measures may be useful. Future work ...

Please provide your email address to receive an email when new articles are posted on . Cancer survivors with increased NT-proBNP levels had an elevated risk for all-cause and cardiac mortality.

LONDON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited, a next-generation point of care diagnostics company, today announced it has commenced commercial shipment of its point of care NT-proBNP ...